Last reviewed · How we verify
AZD3355
At a glance
| Generic name | AZD3355 |
|---|---|
| Also known as | Lesogaberan |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Lesogaberan in Chinese Patients With Refractory Reflux Symptoms (PHASE2)
- TLESR-impedance Study in Patients (PHASE2)
- Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients (PHASE2)
- Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms (PHASE2)
- A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience (PHASE2)
- Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI (PHASE2)
- Renal Impairment Study (PHASE1)
- AZD3355 Dose-escalation Study in Healthy Males (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |